Background Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospitalacquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination and metastatic infection.
Introduction
Staphylococcus aureus bloodstream infection, also known as bacteraemia, is one of the most common and serious community-acquired and hospital-acquired bacterial infections worldwide. 1 When S aureus enters the bloodstream it can disseminate to cause metastatic, deep-seated infection of almost any organ, with an associated mortality of approximately 20%. 2 Despite the frequency and severity of S aureus bacteraemia, the optimal antibiotic treatment is uncertain. Fewer than 1600 participants have been enrolled in randomised trials of antibiotic therapy for the treatment of this infection over the past 50 years. 3 Most treatment recommendations are therefore based on observational studies and clinical experience. Opinions on best management vary widely, 4 but current guidelines 5 recommend S aureus bacteraemia be treated with at least 14 days of an intravenous β-lactam antibiotic, or a glycopeptide if the bacteria are resistant to meticillin. Combination antibiotic therapy is generally not recommended, except in severe meticillin-resistant S aureus (MRSA) infections (eg, endocarditis and
